Skip to main content
. Author manuscript; available in PMC: 2018 Apr 18.
Published in final edited form as: Circulation. 2017 Feb 3;135(16):1494–1505. doi: 10.1161/CIRCULATIONAHA.116.025505

Table 3.

Association of baseline hs-cTnT with odds of significant change in cardiac structure and function*

Subclinical CVD Measure LV Mass LV End-Diastolic Volume LV Ejection Fraction
Unadjusted + Risk factors Unadjusted + Risk factors Unadjusted + Risk Factors
hs-cTnT category (ng/L)†
 <LOD Reference Reference Reference Reference Reference Reference
 3.0–4.05 1.22
(0.996, 1.49)		 1.25
(0.94, 1.66)		 0.69
(0.47, 1.02)		 0.68
(0.44, 1.03)		 1.11
(0.84, 1.48)		 0.90
(0.67, 1.23)
 4.06–5.42 1.06
(0.86, 1.31)		 0.86
(0.63, 1.16)		 1.29
(0.93, 1.79)		 1.17
(0.81, 1.70)		 1.04
(0.78, 1.38)		 0.86
(0.63, 1.18)
 5.43–7.67 1.28
(1.05, 1.55)		 1.24
(0.92, 1.68)		 1.69
(1.25, 2.30)		 1.65
(1.14, 2.39)		 1.51 (1.15, 1.97)
 1.21
(0.88, 1.65)
 ≥7.68 1.59
(1.33, 1.90)		 1.50
(1.09, 2.07)		 1.89
(1.40, 2.55)		 1.39
(0.93, 2.05)		 1.52
(1.16, 1.98)		 1.06
(0.76, 1.48)
Test for trend p<.001 p=.04 p<.001 p=.006 p<.001 p=0.4
ln(hs-cTnT) 1.17
(1.05, 1.32)		 1.16
(1.00, 1.34)		 1.38
(1.20, 1.59)		 1.19
(0.99, 1.43)		 1.21
(1.08, 1.37)		 1.03
(0.88, 1.19)
*

Significant changes defined as: 1) >12% increase in LV mass; 2) >8% increase in LVEDV; 3) >10% relative decline in LVEF;

†

Categories based on distribution of hs-cTnT among subjects with both baseline and follow-up CMR.

Cell values represent Odds Ratios and respective 95% CIs.

Risk factors: Age, gender, race, SBP, DBP, anti-hypertensive medications, diabetes, smoking, lipids levels, height, weight, estimated GFR, and baseline CMR measure.